Posted: November 11, 2008

Nicast Introduces Hernia Mesh to Exploit Unique Properties of Electrospun Nanofabric

(Nanowerk News) Nicast, developer of medical devices made of electrospun nanofabric, announced today that it will introduce the NovaMesh for the treatment of ventral hernias at Medica 2008 in Germany, November 19-22, 2008. Nicast’s booth is located in Hall 5, Booth NO5.
“NovaMesh is the first hernia mesh to exploit the unique properties of electrospun nanofabric. It offers improved resistance to tissue adhesion on the visceral-facing surface and promotes excellent tissue ingrowth on the fascial surface,” said Nicast CEO Mr. Benjamin Eliason.
Nicast will also exhibit the AVflo™ vascular access graft for hemodialysis, its flagship product which received CE certification in October 2008. AVflo, a self-sealing vascular access graft, offers a prime alternative to current products, as it enables unobstructed blood flow, allows for dialysis within 24-48 hours after implantation and self-seals within less than five minutes following withdrawal of the dialysis needles. It is simple to implant and to suture to blood vessels; the needle punctures and suture holes seal rapidly. AVflo is also strong enough to withstand the pressure of blood flow, yet thin enough for blood flow to be easily felt through it. Nicast is currently in discussions with distributors from the EU and Asian countries regarding first distribution agreements of this device.
“Nicast is one of the few companies with expertise in the use of electrospinning. The company’s extensive product line is built on its many patents and various technology platforms. Other products in development at Nicast include non-metallic stents, a spinal disc device and drug release devices. We are looking forward to showcasing our products and to speaking with potential partners and distributors at Medica,” said Dr. Jacob Dagan, chairman of the board of Nicast.
About Nicast Ltd.
Nicast Ltd. is a pioneer in the development of superior implantable medical devices made of electrospun polymer nanofabrics for a wide range of applications. The company is currently focused on the development and marketing of the AVflo vascular access graft and the NovaMesh ventral hernia mesh, which address a combined global market of $0.7 billion to $1 billion. Headquartered in Lod, Israel, Nicast has six patents in the U.S., ten patents outside of the U.S. and 14 additional patents pending. For more information please visit the company’s new web site at
Source: Nicast (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: